Grifols, S.A.
Volume 164 · 164 F.T.C. 1065
Cite this decision
Grifols, S.A., 164 F.T.C. 1065 (2017). Consumer Law Library, https://consumerlawlibrary.org/decisions/v164-0024
Report an error in this record (decision id v164-0024)
Cited by 0 later FTC decisions
Cites
Text (OCR of the scan at left; may contain errors)
IN THE MATTER OF GRIFOLS, S.A.
AND TALECRIS BIOTHERAPEUTICS HOLDINGS CORP.
Docket No. C-4322. Order, September 5, 2017 Letter Order approving the Application filed by Grifols, S.A. to modify the Contract Manufacturing Agreement.
LETTER ORDER APPROVING MODIFICATION John R. Ingrassia, Esq.
Proskauer Rose LLP Counsel for Grifols, S.A.
Re: In the Matter of Grifols, S.A., and Talecris Biotherapeutics Holdings Corp. Docket No. C-4322 Dear Mr. Ingrassia:
Pursuant to Rule 2.41(f) of the Commission Rules of Practice, the Commission has determined to approve the Application filed by Grifols, S.A., on June 12, 2017, to modify the Contract Manufacturing Agreement (“CMA”) incorporated into the Decision and Order in this matter by approving the draft Amendment to the CMA. In according its approval to Grifol’s Application, the Commission has relied upon the information submitted by Grifols S.A., and the Commission has assumed that information to be accurate and complete. By direction of the Commission.
VOLUME 164 Interlocutory Orders, Etc.